CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-0157
Issued: 2026-09-03

PRODUCT IDENTIFICATION

PRODUCT FOXO4-DRI 10mg	SKU / INTERNAL CODE CRF-2026-0157	PRESENTATION Lyophilised powder, 10mg vial
BATCH NUMBER CRF-2026-0157	SAMPLE RECEIVED 2026-08-27	PRODUCTION DATE 2026-08-22
ANALYSIS DATE 2026-09-01	EXPIRY / RETEST DATE 2028-09-01	MOLECULAR FORMULA C228H388N86O64
MOLECULAR WEIGHT (G/MOL) 5358.06	CAS 2460055-10-9	

Research Use Only (RUO). Not for human or veterinary use, consumption, or clinical diagnosis.

ANALYTICAL METHOD — HPLC

INSTRUMENT Thermo Q-Exactive	COLUMN C4 2.1×100mm	COLUMN TEMPERATURE 60°C
MOBILE PHASE A 0.1% TFA H2O	MOBILE PHASE B ACN	FLOW RATE 0.3 mL/min
DETECTION WAVELENGTH 214 nm	INJECTION VOLUME 5 µL	SAMPLE CONCENTRATION 0.5 mg/mL
DILUENT —	RETENTION TIME (MAIN PEAK) 14.5 min	

Recorded methods: HPLC-UV (214 nm) · LC-MS/MS · LAL · ICP-MS

RESULTS

Test	Acceptance Criteria	Result	Verdict
HPLC Purity (% area)	≥98.0%	99.4%	PASS
Identity (LC-MS)	5359.2 ±2%	Obs: 5359.6 [M+H]+	PASS

Verify document: VEL-b9f49be3fc1310d0 · crafalab.com/verify
RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE
Applies only to batch CRF-2026-0157. Certificate CRF-2026-0157.
CRAFA · crafalab.com

Test	Acceptance Criteria	Result	Verdict
Quantity found	95.0–105.0%	9.94 mg (99.4%)	PASS
Endotoxin	<1.0 EU/mg	<0.25 EU/mg	PASS
Heavy metals	<10 ppm	All <LOQ	PASS

Detected Impurities

No impurity data recorded.

FINAL BATCH RESULT

PASS — Conforms to specifications

No chromatogram data recorded.

Analyst notes: Category: Longevity. Sample conforms to label claim and Gold panel acceptance criteria.

crafa

CRAFA